
Regenxbio Investor Relations Material
Latest events

Q4 2024
Regenxbio
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Regenxbio Inc
Access all reports
REGENXBIO is a clinical-stage biotechnology company that provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration.
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
RGNX
Country
🇺🇸 United States